- **05/2023: JeniVision Receives Positive Feedback from Pre-IND Meeting with FDA for JV-MD2 via NIODP for Prevention of Retinopathy of Prematurity (ROP)**.
- **02/2023: Dr. Jenny Wang, JeniVision CEO, Invited to Present at the Prestigious International Society for Eye Research (ISER) XXV Biennial Meeting,** on "New Perspectives on Ocular Biodisposition from Studies on the Anti-Glaucoma Drug JV-GL1" at the Glaucoma Pharmacology Session. https://iserbiennialmeeting2023.org/
- **06/2022: JeniVision Receives Rare Pediatric Disease Designation from the U.S. FDA for JV-MD2 via NIODP for prevention of Retinopathy of Prematurity (ROP)**.
- **02/2022: JeniVision Completes Enrollment to Phase 1B of JV-GL1 Glaucoma Clinical Trial** with preliminary results showing excellent safety profile and good efficacy.
- **12/2021: JeniVision Receives Positive Feedback from Pre-IND Meeting with FDA for JV-DE1 Ophthalmic Solution,** a potent, dual prostanoid IP and PAF receptor antagonist, for treatment of signs and symptoms of dry eye disease.
- **12/2021: Dr. Jenny Wang, JeniVision CEO, to Present at OIS Drug Delivery Innovation Showcase on "Retinal Drugs Delivered by Non-Invasive Ocular Delivery Platform".** To watch the presentation recording please visit https://vimeo.com/652570757
- **03/2021: JeniVision Discovery of Self-Administered, Non-Invasive Ocular Delivery Platform (NIODP).**
- **01/2021: JeniVision Receives FDA Safe to Proceed Letter for IND Application for JV-GL1,** a potent EP2 receptor agonist, in patients with open angle glaucoma or ocular hypertension.
- **11/2018: JeniVision Raises $7M Series A Funding Round from 3 Venture Capital Firms.**
- **2017: JV-GL1 and JV-DE1 patents granted by USPTO**